Mylan NV (NASDAQ:MYL) took another beating today as the heat mounted over their Epipen price gouging. The company recently raised the price by 400% and it has now become a political firestorm. While the stock tanks, smart investors see opportunity. Mylan is not a one drug or Epipen pony. After a certain discount has been priced in, the stock will begin to rally again. The buy level based on technical analysis is $37.75.